Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)

Trial Profile

Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACP 001 (Primary) ; Growth hormones
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms TransCon PEG hGH
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 19 Mar 2018 According to Ascendis Pharma media release, interim data from this trial will be presented at ENDO 2018
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2016 Results assessing optimal release profile of unmodified hGH from the prodrug and to predict the relationship between TransCon Growth Hormone dose and serum concentrations of released unmodified hGH presented at The 98th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top